Allurion Technologies (ALUR) Registration Filing summary

Company overview and business model

• Focuses on a weight loss platform featuring a swallowable, procedureless intragastric balloon (Allurion Smart Capsule) and AI-powered remote patient monitoring tools, behavior change programs, and telehealth services delivered via the Allurion Virtual Care Suite.

• Products are sold internationally, with a premarket application submitted to the FDA for U.S. approval.

• The platform is designed for metabolically healthy weight loss, aiming for fat reduction while maintaining muscle mass, and is compatible with other weight loss therapies.

Financial performance and metrics

• As of January 5, 2026, there were 12,279,181 shares of common stock outstanding and no preferred stock outstanding.

• The last quoted sale price for common stock on January 8, 2026, was $1.70 per share on the NYSE.

Use of proceeds and capital allocation

• May receive up to $5.0 million in cash proceeds from the exercise of November 2025 Private Placement Warrants; proceeds will be used for working capital and general corporate purposes.

• Pending use, proceeds may be invested in investment-grade, interest-bearing securities or held as cash.